Floatz logo

Carfilzomib

Adult Nasal Type Extranodal NK/T-cell Lymphoma

University of NebraskaSmall moleculePhase 1Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

53 Active assets in the Adult Nasal Type Extranodal NK/T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
PEGASPARGASE
CStone Pharmaceuticals
Phase 4BBB
DEXAMETHASONE
Mingzhi Zhang
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Centre, Singapore
Phase 4BBB
Tucidinostat
Ruijin Hospital
Phase 4BB
ETOPOSIDE
Tarapeutics Science Inc.
Phase 4BB

View all 50 →

Same molecule, other indications

Carfilzomib is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
MRDDormant
BB
Indicative ·
64 / 100
View asset →
Stage III Adult Diffuse Large Cell LymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →